Profile
Leti McManus currently works as a Director at mimiX Biotherapeutics Ltd.
Leti McManus active positions
Companies | Position | Start |
---|---|---|
Mimix Biotherapeutics Sàrl
Mimix Biotherapeutics Sàrl BiotechnologyHealth Technology Mimix Biotherapeutics Sàrl is a private company located in Switzerland that develops and commercializes a platform to overcome limitations in tissue engineering, specifically the vascularization challenge and the need for high cell quantities. The Swiss company creates biological architectures with sound using sound-induced morphogenesis, which is a gentle, fast, and easy method to generate multi-cellular, spatially orchestrated tissue constructs using sound waves. The company offers guides for patterning parameters and cells in various hydrogels, including collagen, fibrin, gelatine, and synthetic hydrogels. The company's FastSkin® technology combines micrografting with sound-induced morphogenesis to improve wound care management, addressing a major social burden and unmet clinical need in oncology and chronic wounds treatments. Mimix Biotherapeutics also provides control over cellular and extracellular organization at high spatial resolution to investigate cell-material interactions in vitro models. | Director/Board Member | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 1 |
---|---|
Mimix Biotherapeutics Sàrl
Mimix Biotherapeutics Sàrl BiotechnologyHealth Technology Mimix Biotherapeutics Sàrl is a private company located in Switzerland that develops and commercializes a platform to overcome limitations in tissue engineering, specifically the vascularization challenge and the need for high cell quantities. The Swiss company creates biological architectures with sound using sound-induced morphogenesis, which is a gentle, fast, and easy method to generate multi-cellular, spatially orchestrated tissue constructs using sound waves. The company offers guides for patterning parameters and cells in various hydrogels, including collagen, fibrin, gelatine, and synthetic hydrogels. The company's FastSkin® technology combines micrografting with sound-induced morphogenesis to improve wound care management, addressing a major social burden and unmet clinical need in oncology and chronic wounds treatments. Mimix Biotherapeutics also provides control over cellular and extracellular organization at high spatial resolution to investigate cell-material interactions in vitro models. | Health Technology |
- Stock Market
- Insiders
- Leti McManus